Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Dr Seth Lederman spoke to Proactive on the group's financial results for the fourth quarter and full year, along with an update on its second Phase 3 study of fibromyalgia.
Dr Lederman says it recently enrolled the first 50% of patients in its RALLY study. The RALLY study uses the same design as the company’s first positive Phase 3 study, RELIEF, but with an additional 200 patients. Top-line results are expected by the end of 2021.